Barbara A. Murphy
Vanderbilt University Medical Center · 303 works · 13,673 citations · h-index 54
Top works
- CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment
- Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma
- Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
- Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
- Phase III Trial of Interferon Alfa-2a With or Without 13-cis-Retinoic Acid for Patients With Advanced Renal Cell Carcinoma
- Phase II Trial of Gemcitabine Plus Cisplatin in Patients With Metastatic Urothelial Cancer
- Increased Epidermal Growth Factor Receptor Gene Copy Number Is Associated With Poor Prognosis in Head and Neck Squamous Cell Carcinomas
- Randomized Phase III Evaluation of Cisplatin Plus Fluorouracil Versus Cisplatin Plus Paclitaxel in Advanced Head and Neck Cancer (E1395): An Intergroup Trial of the Eastern Cooperative Oncology Group
- Cancer-Related Fatigue, Version 2.2015
- Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities
- Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro.
- Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial.
- E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx— ECOG-ACRIN Cancer Research Group
- Gene Expression Differences Associated with Human Papillomavirus Status in Head and Neck Squamous Cell Carcinoma
- Adult Cancer Pain
- Oral complications of cancer and cancer therapy
- Phase II Trial of Chemoradiation for Organ Preservation in Resectable Stage III or IV Squamous Cell Carcinomas of the Larynx or Oropharynx: Results of Eastern Cooperative Oncology Group Study E2399
- Phase III Comparison of High-Dose Paclitaxel + Cisplatin + Granulocyte Colony-Stimulating Factor Versus Low-Dose Paclitaxel + Cisplatin in Advanced Head and Neck Cancer: Eastern Cooperative Oncology Group Study E1393
- Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline
- Quality of life research in head and neck cancer: A review of the current state of the science